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Metastatic melanoma is a malignant cancer with generally poor prognosis, with no targeted chemotherapy.
To identify epigenetic changes related to melanoma, we have determined genome-wide methylated CpG
island distributions by next-generation sequencing. Melanoma chromosomes tend to be differentially
methylated over short CpG island tracts. CpG islands in the upstream regulatory regions of many coding
and noncoding RNA genes, including, for example, TERC, which encodes the telomerase RNA, exhibit
extensive hypermethylation, whereas several repeated elements, such as LINE 2, and several LTR elements,
are hypomethylated in advanced stage melanoma cell lines. By using CpG island demethylation profiles, and
by integrating these data with RNA-seq data obtained from melanoma cells, we have identified a
co-expression network of differentially methylated genes with significance for cancer related functions.
Focused assays of melanoma patient tissue samples for CpG island methylation near the noncoding RNA
gene SNORD-10 demonstrated high specificity.
M
elanoma, a lethal form of skin cancer whose risk is increasing in the United States, is difficult to diagnose
early and has been refractory to targeted chemotherapy1. While it is generally true that melanomas are
caused by ultraviolet B induced lesions in melanocytes of the skin, the exact molecular events leading to
melanoma production are yet unknown2. Over 90% of melanomas are independent of TP53 gene mutation3,
suggesting pathways other than those involved in p53 mediated DNA repair or abrogation of apoptosis by p53 are
generally not directly involved. Early events in melanoma induction involve epithelial-mesenchymal transition,
and both protein coding and noncoding RNA genes are important4. Several protein-coding genes have been
identified as candidate drug targets and potential early biomarkers for aggressive melanoma5–11, of which several
exhibit distinct expression signatures among a variety of malignant metastatic melanomas and their benign
forms12–14. However, there are unquestioned needs for further understanding the molecular mechanisms of
melanoma development and progression, and to develop additional sensitive and specific early diagnostic
biomarkers. An important question for both understanding the biology of melanomas and for better biomarker
discovery is the role of epigenetic modification, such as CpG methylation and chromatin protein modification, in
differential expression of genes during melanoma initiation and progression.
Aberrant methylation of promoter CpG islands resulting directly from the activities of cytosine DNA methyl-
transferases15 is frequently involved in cancers16. Three DNA methyltransferase genes, DNMT1, DNMT3A, and
DNMT3B, are directly responsible for DNA CpG island methylation17,18, and approximately 50 genes are regu-
lated, at least in part, by hypermethylation of CpG islands in their respective regulatory regions in human
melanomas19. Of these, RASSF1 is a hallmark gene for abnormal methylation in many cancers including meta-
static melanomas20,21. Among genes that exhibit differential CpG island modification in their putative regulatory
regions are the non-protein coding RNAs (ncRNAs). Small ncRNA molecules such as microRNAs (miRNAs)
have garnered increasing attention for their potential roles in tumorigenesis22–26, including in melanoma11,27–34.
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genes and oncogenes34–40. Since miRNA precursor genes are usually
nested within other protein coding genes, often within intron
sequences, the misregulation of these protein-coding genes by epi-
genetic mechanisms is expected to cause aberrant regulation of the
miRNA target genes. miRNA gene silencing by CpG island methyla-
tion has been reported in several cancers41–43, although little is known
in this regard for melanomas44. Our previous results with melanoma
cell lines and clinical samples demonstrated that the expression of
several miRNA species is epigenetically regulated in human mela-
noma and we have recently reported on the molecular mechanisms
by which two such miRNAs, miR-375 and miR-34b, might affect
melanoma development in humans45,46.
While it is generally thought that differentiated melanocytes must
first dedifferentiate and then undergo transformation due to success-
ive mutations, there are also reports of melanoma stem cells47,48.
Recently, a mutational signature of melanoma cells sampled from
multiple melanoma subtypes has been described49–51. Additionally, a
recent landmark study50 finds numerous mutations distributed over
the melanoma genome, including many inter and intra-chromo-
somal rearrangements reminiscent of chromothripsis52 and numer-
ous single base changes that bear the preferential C R T transition
bias expected of UV mutagenesis (including in BRAF, PTEN, and
PTEN-interacting genes). These studies underscore the significant
role that genome rearrangements and point mutations, presumably
induced by UV radiation, evidently play in melanoma development.
It not clear, however, how these mutations contribute to melanoma
development, and whether (or what fraction of) UV induced muta-
tions are the primary causes or indirect effects of epigenetic repro-
gramming that evidently accompanies melanoma progression. Here
we examine a related question: do melanocytes and melanoma cells
that have been established from distinct melanoma stages differ in
their epigenetic signatures? By understanding the epigenetic changes
in the coding and noncoding RNA genes during melanoma progres-
sion it might be possible to obtain an additional perspective of the
molecular mechanisms and point towards more effective biomarker
development for melanoma prognosis. The melanoma epigenome is
complex53; here we focus on a small subset of the melanoma epigen-
ome—the genome-wide CpG island methylation status.
Characterization of methylated CpG islands genome-wide has
been conducted in the past by either direct bisulfite sequencing54,
by methylation sensitive restriction endonuclease site mapping55,
high resolution melt sequencing56,57, and by enriching methylated
cytidines using a monoclonal antibody58,59. Methyl binding domain
2 protein (MBD2) has been used to specifically pull-down methy-
lated CpG islands with high efficiency and specificity in a focused
study of CpG island methylation of selected genes60.
Compared to other methods, such as direct bisulfite sequencing,
MBD2 allows rapid and selective identification of highly methylated
CpG islands61,62, but suffers from under-estimation of the total spec-
trum of CpG methylation because CpG methylation in non-island
sites are generally ignored. However, the relative merits of these
distinct techniques for genome wide methylome analysis are cur-
rently difficult to evaluate because a head-to-head comparison of
these assays has not yet been performed63. We have used MBD2 pull
down for its high throughput capabilities and also because of its
recent reported use in characterizing the methylomes of cancer cell
lines other than melanoma62. Here, we report for the first time the
characterization of the global melanoma CpG island methylome by
MBD2-mediated pull-down, followed by next generation sequencing
performed on samples from four different melanoma cell lines. We
have characterized the CpG island methylation patterns in the reg-
ulatory regions of coding and noncoding RNA genes in melanoma-
derived cell lines, melanoma patient samples, melanocytic nevi and
normal melanocytes. The large number of coding and noncoding
methylated regions identified in this study will be a resource for
cancer biologists interested in the epigenomics of melanoma
progression. We have discovered that under-methylated CpG islands
are associated with certain Alu elements and retrotransposable ele-
ments in late stage melanoma cell lines in contrast with those in early
stage melanoma cells and melanocytes. Finally, we present genome
wide methyl CpG island signatures that are characteristic of mela-
nocytes, of early stage and of late stage melanomas, respectively.
These results are in agreement with the notion that melanocytes
undergo progressive hypomethylation across large tracts of CpG
islands genome-wide as these are transformed into early stage mel-
anomas, followed by extensive hypermethylation as late stage mela-
nomas develop. Coupled with the recent report of pervasive
transposable element movements in several epithelial cancer gen-
omes and their correlation with regions of cancer-specific DNA
hypomethylation tracts64, and the presumed role of these elements
in causing mutagenesis, our results underscore the importance of
methyl CpG dynamics during melanoma progression.
Results
Genomic CpG islands are differentially methylated in melanoma
cells. To identify the highly methylated regions in the melanoma
genome, we used methyl-CpG-binding protein (MBD2) to pull
down methylated CpG islands of human melanoma cell lines and
normal melanocytes (HEM-l), and the enriched sequences were
subjected to deep-sequencing (see Methods). The melanoma cell
lines were obtained from (A) stage I primary melanoma vertical
growth phase: WM793B; (B) invasive metastatic melanoma stage
III (radial growth phase): WM1552C; and (C) distant metastatic
stage IV: A375 and SK-MEL2. The raw DNA sequence data were
first examined for their sequence quality and then the reads with
average quality values over 20 (see Methods) were mapped to the
version hg19 reference human genome. MBD2 enriched regions
were further analyzed for cell-type specific methylation patterns.
The total numbers of initial peak sequence calls (563 K) (Fig. 1A)
were further partitioned and mapped to regions 3 kb upstream
of transcriptional start site (TSS), and 3 kb downstream of
transcription end sites (TES) of protein coding genes. In total,
365 K peak MBD2-enriched sequenced regions could be aligned to
18,716 genes based on the above criteria (Fig. 1A). The remaining
robust MBD2-pulldown sequence peaks either mapped to
unannotated regions, or mapped to ncRNA and/or repetitive DNA
regions (see later). Figure 1B shows the frequency distribution of
unique MBD2-pulldown DNA of various cell lines. Melanocytes
(control cells) showed relatively low levels of MBD2-pulldown
DNA compared to those in the melanoma cells, however, there
were two distinct peaks at 275 and 450 bp, respectively. By
contrast, the stage III line WM1552C and stage IV lines SK-MEL2
and A375 displayed enriched MBD2-pulldown tracts of shorter
lengths on average than those seen with the stage I line WM793B.
Melanocytes (145,221 peaks) and the stage I melanoma line
WM793B (113,657 peaks) showed half as many MBD2-pulldown
peaks than the other melanoma cell lines (WM1552C, 284,533;
SK-MEL2, 263,796; and A375, 216,021 peaks, respectively.
Supplementary Table S1). Furthermore, the cell lines that were
enriched for the total segments of MBD2-pulldown DNA had on
average shorter DNA stretches than those with fewer segments of
MBD2-pulldown DNA. For most cell lines two peaks, one at , 200–
300 bp and another at , 350–450 bp, or a broad peak with a hint of a
shoulder (for A375) could be discerned.
To determine whether the MBD2-enriched DNA corresponded to
methylated CpG islands, we conducted targeted bisulphite sequen-
cing of MBD2-pulldown DNA at five genes (PCSK1, CYP1B1,
QPCT, c-KIT, and TERC). These genes were selected on the basis
of methyl-CpG levels in their upstream regulatory regions shown in
the MBD2-pulldown experiments and of their existence in previous
reports of differential methylation in melanoma or cancer cells53,65.
Here we found a complete correlation between hypermethylated
www.nature.com/scientificreports
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CpG islands in the MBD2-pulldown DNA and high level of CpG
methylation by bisulfite sequencing (Fig. 2). These results show that
for all practical purposes, the MBD2-pulldown DNA corresponds to
highly methylated CpG island DNA.
Figure 1C shows the number of highly methylated CpG islands
shared or unique among the melanocyte, WM793B (stage I) and
WM1552C (stage III) cell lines. Likewise in Figure 1D, the numbers
of methyl-CpG islands in 2 stage IV lines are compared, which shows
that 105,182 methylated CpG islands are in common. To identify the
methyl CpG islands unique to stage IV lines, we intersected this core
set of 105,182 islands with those of melanocytes, stage I, and stage III
lines, and obtained a set of 19,686 islands (Fig. 1E). Of these, 14,849
regions could be aligned to 5,700 annotated genes with the condition
that the query regions were located within a sequence window con-
taining 3 kb upstream of TSS and 3 kb downstream of TES, includ-
ing the entire set of introns and exons for every gene. When the
sequence windows were reduced to regulatory region (2 kb upstream
and 1 kb downstream of TSS), 885 regions could be aligned to 821
unique genes. Functional analysis revealed that these 821 genes are
statistically enriched for important developmental pathways and cell
biological functions, including stem cell differentiation (p 5 3.09 3
1024), cellular movement (p 5 9.59 3 1025), cell morphology (p 5
1.34 3 1023), connective tissue development (p 5 1.34 3 1023) and
embryonic development (p 5 1.34 3 1023) (Supplementary Fig.
S1A–D). Figure 1F shows circular plots of chromosome-wide methyl
CpG island peaks for all cell lines. Some chromosomes, such as
Figure 1 | Characterization of genome-wide methylation patterns in melanoma cell lines. (A) The overall workflow, and results of next-generation
sequencing and analysis of MBD2-pulldown DNA. (B) Frequency distributions of sizes of the MBD2-pulldown DNA across five cell lines. The methylated
regions were defined by MACS peak calling of the MBD2-pulldown DNA against input (non-enriched) DNA. (C) & (D) Venn diagram of the number of
MBD2-pulldown regions shared or unique among the various cell lines. (E) Venn diagram describing the number of MBD2-pulldown DNA regions
partitioned among various cell lines, which defines a unique set of stage IV specific MBD2-pulldown DNA regions. (F) Genome-wide distribution of
differential methylated regions (as defined as the MBD2-pulldown DNA). The outermost circle displays the human chromosomes. The inner circles
represent the genome-wide distribution of MBD2-pulldown DNA. The height of the histogram bins indicates the density of methylated regions. From the
inner most circle, which represents the distribution of MBD2-pulldown DNA in 5AzadC treated WM1552C (black), the circles from inside going outside
represent HEM-1 (orange), WM793B (blue), WM1552C (green), A375 (red) and SKEML2 (red).
www.nature.com/scientificreports
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Figure 2 | DNA fragments pulled-down with MBD2 are enriched for methylated CpG islands. Results of bisulfite sequencing of MBD2-pulldown DNA
near five genes are shown. Methylated CpG sequences are shown as closed boxes (unmethylated sequences are open boxes). The number at the
right of each row corresponds to the number of CpG in the region that was methylated, with the total number of CpG represented as the total number of
boxes in each row. Each row is an independent experiment.
www.nature.com/scientificreports
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chromosomes 4, 6, 8 and 13, appear to have on average fewer methyl
CpG island peaks compared to several others, such as chromosomes
1, 16, 17, 19, and 20.
Methyl CpG islands in genic and non-genic regions. We sought to
ascribe the CpG islands to genic and non-genic regions in the follow-
ing way. The genomic regions were separated into six functional
categories: promoter region (up to 3 Kb upstream of transcription
start sites or TSS), 5’UTR, exon, intron, 3’UTR, and downstream
region (up to 3 Kb downstream of the stop codon). Some of the
downstream sequence regions overlapped with 3’UTR of a given
gene. For peaks that belonged to multiple genomic regions, the
length of the overlapped regions broke the ties. For example, if a
peak overlapped 300 bp with a gene’s promoter region and 400 bp
with another gene’s intronic region, the peak was assigned as an
intronic region. Each peak was assigned to a specific genomic
interval and the highest numbers of tag counts were seen between
100 bp and 400 bp tag lengths, but the lengths of the methyl-CpG
islands extended 100–800 bp (Fig. 1B). Tag counts of all melanoma
cell lines and melanocytes were normalized to that of WM1552C
input (non-enriched) DNA. Figure 3A summarizes these results.
In general, the extent of methyl CpG islands is higher in the stage
III and stage IV cell lines than that of any other cell lines. The exon
and intron regions of the stage I cells have significantly reduced
methylated CpG islands compared to the corresponding regions of
any other cell line including the precursor melanocytes (Supplemen-
tary Table S2). With respect to the distribution of methyl CpG
islands, the stage III and IV cell lines were mutually indistingui-
shable, but these two stages were distinguishable from the
melanocytes and the stage I cell line in all of the genomic intervals
monitored. That these differences are biologically significant is
shown by clustering the methyl CpG-enriched DNA from 6
1000 bp of the TSS of cancer-related genes extracted from the
datasets66 (Fig. 3B): the extent of methylated CpG islands
corresponding to the promoter regions of cancer-related genes in
the two stage IV lines clustered together, followed by those in the
stage III line; those in the stage I line were the furthest away from the
two stage IV lines. These results demonstrate that in as much as
known cancer-related genes are concerned, their regulatory regions
are differentially methylated at the CpG islands in stage III and IV
cells relative to melanocytes and the stage I cell line.
Reversal of methylation at CpG islands by DNA methyl trans-
ferase inhibition reveals a transcriptionally co-regulated gene
network. In this section we address the functional significance of
differential promoter hypermethylation in stage III–IV cells. We first
depleted methyl-CpG of the stage III WM1552C cells with 5AzadC
treatment and compared the relative abundance of methyl-CpGs
that could be depleted in these cells with those in untreated cells.
5AzadC concentration was chosen on the basis of our previous
studies, which showed a nearly complete loss of CpG methylation
combined with induction of gene expression in CpG-dense
promoters45,46. We pulled down MBD2 bound DNA, and subjected
these to next generation sequencing as described before. In the total
sequenced dataset, we focused specifically on methyl-CpG stretches
located within 2 kb upstream and 1 kb downstream of the transcrip-
tion start site (TSS) of coding genes. This process generated 7,590
regions corresponding to 5,637 genes. We further filtered this
number by incorporating nearby CpG island information from the
UCSC human genome database, and promoter information from the
eukaryotic promoter database67, in a 1 kb upstream region of each
TSS. This yielded 583 highly methylated upstream regulatory regions
corresponding to 581 genes. Figure 3C illustrates the enrichment of
Gene Ontology (GO) functional category of Diseases and Disorders.
Enrichment data for other functional categories (physiological
system development and molecular and cellular function) are
provided in Supplementary Figure S2 and a list of these 583
regions (581 genes) is in Supplementary Table S3.
To validate whether the methylated CpG islands that could be
erased by treatment with 5AzadC correlated with silenced genes in
melanoma cells, we determined the extent of CpG island methylation
in the regulatory regions of the set of 581 genes with RNA abundance
data (RNA-seq) from melanocytes and WM1552C (Supplementary
Table S3). Here also, the two stage IV cell lines (A375, and SK-MEL2)
resembled the CpG island methylation patterns of the stage III line
WM1552C. Interestingly, the CpG islands in the upstream region of
PCSK1 are methylated in WM1552C but not in any of the other
tested cell lines (Supplementary Fig. S3A). We also examined the
methylation status of two noncoding RNA genes—the telomerase
RNA gene, TERC and the snoRNA gene SNORD-10. The reason
for choosing these two genes was that the expression of these tran-
scripts showed a considerable down-regulation in WM1552C and
transcript levels of both genes were up-regulated upon treatment
with 5AzadC. The upstream putative promoter regions of both
TERC and SNORD-10 ncRNA are highly methylated at the CpG
islands, and are reversed upon treatment with 5AzadC (Supplemen-
tary Fig. S3B and Fig. 4A).
We queried a database of cancer-related human gene expression68
(containing 1,180,670 interactions) for correlated gene expression
levels between all pairs of genes from the list of 581 genes above.
This yielded a fully connected network of 554 co-expressed genes
(Fig. S4) (and 68 unconnected genes), suggesting that this subset of
554 genes is under coordinate regulation by a common set of tran-
scription factors or epigenetic regulators. This co-expression net-
work fits a power law degree distribution (exponent c 5 21.6; R2
5 0.803), suggesting that it is a biologically robust network69. The
554-member co-expression network was significantly enriched
(Benjamini-Hochberg (B-H) corrected P 5 1.47 3 1028) for the
Gene Ontology (GO) molecular functional annotation of
‘‘sequence-specific DNA binding’’ (GO:0043565) (36/581 input
query genes), and ‘‘sequence-specific DNA-binding transcriptional
factor’’ (GO:0003700) (B-H corrected P 5 1.16 3 1026; 48/581 query
genes) as anticipated for a transcriptional co-expression network.
Moreover, the network was also enriched (B-H corrected P 5 3.4
3 1028) for ‘‘alpha-2 macroglobulin receptor-associated protein
activity’’ (GO:0005515) and contains 191/581 input genes in this
annotation cluster. The full set of GO enrichment categories along
with B-H corrected P values are provided in Supplementary Table S4.
To further investigate the possible functions of this group of genes,
we queried the human protein-protein interaction database with this
gene set for inclusion of the member gene products in known protein
complexes. We discovered 5 protein modules having 3 or more
members (Fig. 5A–E), with no statistically significant functional
enrichment, expected because transcriptional networks do not
necessarily correspond to protein-protein interaction networks.
We therefore queried integrated protein-protein interactome data-
bases for first-degree neighbors of each of these module members,
thus expanding the respective modules (Fig. 5F–J). These first degree
expanded protein modules were statistically significantly enriched
for RNA-dependent DNA replication/telomere maintenance via tel-
omerase (B-H corrected P 5 7.83 3 1023) (Fig. 5F); ligand dependent
transcription factor activity (B-H corrected P 5 3.43 3 1022)
(Fig. 5G); Tumor Necrosis Factor (TNF) binding (B-H corrected P
5 6.95 3 1024) and p53 mediated DNA damage response (B-H
corrected P 5 2.47 3 1022) (Fig. 5H); basal lamella (B-H corrected
P 5 1.68 3 10210) and substrate dependent cell movement (B-H
corrected P 5 6.28 3 1024) (Fig. 5I); and actin filament sliding (B-
H corrected P 5 8.22 3 1023) and endocytosis (B-H corrected P 5
2.06 3 1022) (Fig. 5J).
Methyl CpG islands associated with repeated DNA elements.
Given that one of the expanded protein modules discovered above
www.nature.com/scientificreports
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Figure 3 | Functional significance of methylated CpG islands in melanoma cells. (A) The functional class distribution of CpG methylation in the five cell
lines. Gene annotation was taken from Refseq at UCSC genome browser. Promoter region was defined as 3000 bp upstream of the transcription starting
site (TSS), and the downstream region is defined as 3000 bp downstream of translation stop sequence. (B) Heatmap of methylation fold change in
6 1000 bp windows centered at TSS for cancer related genes in the five cell lines. The rows represent 3,688 cancer-related genes downloaded from the
CancerGene database by Higgin et al.66, which were filtered for significant methyl CpG levels in melanoma lines relative to HEM-1. Color scale on the right
represents MBD2-enrichment, i.e., methyl CpG, fold change. (C) Functional enrichment analysis of diseases and disorders of the gene set in (B).
www.nature.com/scientificreports
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is enriched for RNA-dependent DNA replication, and the suspected
role of retrotransposable elements in causing large-scale genomic
rearrangements in cancer, we looked for the evidence of altered
CpG island methylation associated with repeated DNA elements in
melanoma cell lines and compared these against the melanocyte
derived cell line (HEM-l). Among the 14 classes of repeated ele-
ments we tracked, 11 classes were associated with relatively hypome-
thylated CpG islands in late stage melanomas (WM1552C, SK-MEL2,
and A375) compared to their methylation status in melanocytes
(Fig. 6). The methylation levels of the CpG islands associated with
7 of these 11 elements appeared relatively unchanged in the
remaining melanoma cell lines including the Stage I line WM793B,
the remaining four showing a slight bias towards hypomethylation.
Strikingly, three repeat element classes (simple repeats, LINE-1
elements, and SINE Alu repeats) showed the opposite tendency:
hypermethylation in WM1552C, SK-MEL2 and A375 cells relative
Figure 4 | CpG methylation status near SNOR-10 gene in different patient samples. (A) depicts the results obtained with next-generation sequencing of
MBD2-enriched DNA in the five cell lines, plus those in WM1552C cells treated with 5AzadC and those in the input DNA. (B) A region between 2249 bp
and 231 bp of the TSS of SNORD-10 is shown magnified. Methylation status of this region in the DNA obtained from various metastatic melanoma
patient samples or in non-melanoma nevi was determined by bisulfite sequencing (see Methods). Each box is a CpG; open boxes are unmethylated, filled
boxes are methyl CpG sequences. Numbers at the right represent the number of methyl CpG detected in the region corresponding to each row
(independent sequence analysis).
www.nature.com/scientificreports
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to HEM-l and WM793B. While these results are consistent with the
notion that some transposable elements characterized by these repeat
elements could become active due to hypomethylation in late stage
melanomas, there is variation with respect to the classes of moveable
elements as well as the exact stage of melanoma development. In
general, it appears that hypomethylated repeat elements are more
frequent in advanced stage melanomas than in stage I or in normal
melanocytes.
Methylated CpG islands show consistent signatures in melanoma
patient samples. To address whether the general patterns of CpG
island methylation discovered above are reflected in frozen tumor
tissue samples obtained from malignant melanoma (stages III and
IV) patients, we measured CpG island methylation status of
upstream regulatory regions of SNORD-10 (Fig. 4B) and c-KIT
(Fig. S5). Unlike the unmethylated CpG islands in non-cancerous
nevi samples, all tumor samples showed variable levels of hyper-
methylated CpG islands. These results suggest that the set of 581
upstream regulatory regions discovered here as differentially
methylated among melanoma cells provide a novel collection of
regions for further subtyping of melanoma cells in future studies.
Muthusamy et al., has previously reported that several coding genes
promoter CpG islands, including PCSK1, QPCT and CYP1B1 have
been methylated in melanoma patient samples and our cell line
results agree with their observations53.
Discussion
We have determined by deep sequencing the genome wide distri-
bution of MBD2-pulldown DNA from one normal melanocyte cell
line and four melanoma cell lines, and by targeted bisulfite sequencing
Figure 5 | MBD2-enriched DNA from WM1552C cells defines a large co-expression network with cancer and metastasis-related genes. A co-expression
network formed by the genes that exhibit (a) enrichment for MBD2-pulldown relative to HEM-l, (b) differential RNA expression levels measured by
RNA-seq relative to HEM-l, and (c) included in cancer-related genes by Higgins et al66. (A)–(E) Proteins of the connected component in the co-repression
network (Fig. S4) that are known to interact as members of known protein complexes. (F)–(J) Protein complexes constructed by extending the core
protein interaction networks in (A–E) as seeds by incorporating known first-degree interaction neighbors of the member proteins. The protein modules
are enriched for RNA-dependent DNA replication (F), ligand-dependent transcription factor activity (G), DNA damage response and cell death (H),
basal lamina/substrate-dependent cell movement (I), and actin filament sliding/cell movement (J) (see text for P-values).
www.nature.com/scientificreports
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have demonstrated that the CpG islands in the MBD2-affinity cap-
tured DNA are enriched for methylated CpG residues. A notable
feature of the results from the stage III and IV melanoma samples
is that CpG islands shorter than , 270 bp were proportionately more
hypermethylated than the longer (. 450 bp) CpG islands when com-
pared with the methylation levels of the corresponding CpG stretches
of normal melanocytes and the stage I melanoma lines. We have
identified a core group of 19,686 CpG island sequences that mapped
to at least 821 genes or their associated regions. The distribution of the
methyl CpG residues within various genic and non-genic features
exhibit statistically significant hypermethylation in the 3 kb upstream
promoter regions, introns and exons in stage III and IV melanoma
cell lines relative to the corresponding features in the normal mela-
nocyte cells. Recently, Kim et al.70 reported that the intronic regions
are highly methylated in prostate cancer; similarly, in our dataset the
highest levels of methyl-CpGs were also associated within intronic
regions, and these regions were equally methylated among all cell
lines, which presumably reflect transcriptionally an inert state of these
DNA stretches. Hansen et al.71 previously reported a study focus on
methylated DNA regions in several cancer types (colon, lung, breast,
thyroid and wilm’s tumors), but not in melanoma.
A large fraction of the hypermethylated CpG islands in the stage
III cell line WM1552C could be erased by treating these cells with
5AzadC. While there are significant hypermethylation of CpG
islands associated with genes and their surrounding regions in the
advanced stage melanoma cell lines, the same cell lines show signifi-
cantly reduced CpG methylation levels associated with LINE1,
LINE2 and various LTR repeat elements. Our observations indicate
that while there is evidence of extensive hypermethylation of genic
and non-genic regions in stage III–IV melanoma cell lines, the
reverse is true of the CpG islands associated with 11 out of 14 types
of repetitive DNA elements. Most of these repetitive retro-elements
are hypomethylated in the stage III–IV groups. Since hypomethyla-
tion of retro-element DNA is known to positively correlate with their
movement, and because previous reports of genome wide studies
have shown increased levels of mutagenesis in melanoma cell lines,
we suggest that a significant proportion of genome wide DNA
sequence alterations in late stage melanoma cells could be due to
retro-element mobilization. However, there are subtle differences
in the behavior of CpG islands associated with retro-element classes.
For example, the CpG islands associated with SINE L1 elements
show the reverse tendencies (are hypermethylated) relative to SINE
L2 elements; similarly, SINE Alu repeat-associated CpG islands are
hypermethylated in the stage III–IV group compared with the SINE
MIR elements. It will be interesting to determine whether the relative
mobility of these elements reflects their corresponding CpG island
methylation patterns.
Among the genes that are differentially methylated at CpG islands
within 1 kb upstream of their TSS, which are also differentially
expressed in the stage III melanoma line WM1552C relative to those
in normal melanocytes, we have identified a group of 554 genes that
appear to be co-expressed in a large dataset of cancer-related gene
expression levels. This group of genes is functionally enriched for
transcription factors, and we suspect that a significant proportion of
these genes might form a network of epigenetic core that are coordi-
nately regulated by methylation at their CpG islands. Interestingly,
this co-expression network is also enriched for alpha-2 macroglobu-
lins, which are known to be over-expressed in melanoma cells72–74,
which may be related to their invasiveness and metastasis72.
Strikingly, this large co-expression network does not appear to be
enriched for members that encode proteins that are part of protein
complexes. However, by systematically querying the current protein-
protein interaction databases, we were able to discover the member-
ships of several of these proteins within five functionally significant
protein complexes: RNA-dependent DNA polymerases, transcrip-
tion factors, DNA damage/cell death response, cell motility, and
basal lamella function. The first of these complexes are known to
be important for retrotranspose on mobility, and the remaining cat-
egories of proteins are all known to be associated with advanced stage
cancers including metastatic cancers. Noteworthy also is the inclu-
sion of laminin, which is a known mitogen for melanoma cells75.
The genome wide data on methylated CpG island regions enriched
in late state melanoma cells relative to melanocytes described here
constitute a resource for cancer biologists and melanoma researchers.
Investigation of the epigenetic control of human melanomas should
contribute to molecular classification of metastatic melanomas; the
resources described here should be useful for these studies. We sug-
gest that the CpG island methylation signatures revealed here should
be important for the development of novel biomarkers, as for example
we have shown a remarkably consistent methyl CpG signature at the
noncoding RNA gene SNORD-10 by direct bisulfite sequencing
selected on the basis of our genome wide data. However, the develop-
ment of such biomarkers would have to depend on further retrospect-
ive and prospective studies on additional patient samples.
In conclusion, we have described genome-wide distribution of
methylated CpG islands in a number of melanoma cell lines, and
have shown that these regions are functionally significant for can-
cerous properties of these cells.
Methods
Cell lines and clinical samples. The experiments performed in this manuscript
utilized the following cells and cell lines: human epidermal melanocyte cell line HEM-
l (acquired from ScienCell, Catalog # 2200; growth conditions: MelM media
containing MelGS supplements with 0.5% FBS and pen/strep), the melanoma cell
lines WM793B (stage 1, ATCCH Number: CRL-2806), WM1552C (stage 3, ATCCH
Figure 6 | Patterns of methyl CpG at repetitive elements enriched in the five cell lines. The relative levels of MBD2-enrichment at repeated DNA
elements compared to input (un-enriched) DNA are plotted in a color coding scheme in which the color represents the enrichment significance P-values.
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Number: CRL-2808), SK-MEL2 (stage 4, ATCC(R)), and A375 (stage 4, ATCCH
Number: CRL-1619). All melanoma cell lines were grown in Complete Tu media: a
451 mixture of MCDB-153 w/1.5 g/L sodium bicarbonate & Leibovitz L-15 with
2 mM L-glutamine, plus 2% FBS and 1.68 mM CaCl2. All clinical samples described
in this publication were acquired from frozen samples graciously donated by Dr.
James Goydos of Robert Wood Johnson Medical School76.
MBD2 pull-down. Genomic DNA was fragmented to 50–400 bp (mean , 250 bp)
using the CovarisTM S2 system (Woburn, MA), and 10 mg of DNA was subjected to
MBD2-protein capture according to the manufacture’s protocol. We used different
concentrations of NaCl enrichment buffer (200 nM, 350 nM, 450 nM, 600 nM, 1 M,
and 2 M) for single fraction elution in A375 cells and observed that the highest salt
concentration (2 M) produced tighter enrichment of CpG islands in the MBD2 pull-
down samples. Therefore, we used 2 M NaCl for all subsequent sample enrichments.
The methylated DNA fragments recovered from the first two incubations of 2 M salt
were pooled, and then ethanol precipitated and resuspended. This DNA or samples of
DNA that did not go through the MBD2 pull-down (whole-genome, non-enriched),
were used for fragment library construction, which included a gel-based size selection
step to obtain a mean fragment length of , 150 bp.
Isolation of genomic DNA and bisulfite treatment. Samples of genomic DNA were
prepared from 107 cells of each cell line. Samples were harvested by trypsinization,
spun down at low speed (1200 rpm), and washed with phosphate-buffered saline
(PBS). Cell pellets were then processed using the QiaAmp DNA mini kit (QIAGEN).
Genomic DNA was harvested from 25 mg of frozen patient samples and isolated by
incubation with proteinase K at 55uC overnight. Samples were purified with the
QiaAmp DNA mini kit (QIAGEN). All sample yields were determined using a ND-
1000 spectrophotometer (Nanodrop). 500 ng of each sample of genomic DNA was
then treated with sodium bisulfite overnight and purified and eluted with the EZ DNA
methylation kit (Zymo Research).
Bisulfite-conversion and amplification. Bisulphite PCR was performed using
genomic eluate with the following primer combinations: PCSK1 Meth For (gggtagata
aggagtagatttaattgattttag) and PCSK1 Meth Rev (ctctaaaccactcctaactcctaattactc) to
amplify a 253 bp region; CYP1B1 Meth For 2 (ggagttgattttttggagaaatggt) and
CYP1B1 Meth Rev (cttaccctaaacaaaaatcccaattccttc) to amplify a 301 bp region;
QPCT Meth For (gggtttagaagtttgtgtttgttatttaggg) and QPCT Meth Rev 3 (cccaaaacaa
aacgaccaccaacaacaac) to amplify a 243 bp region; TERC Meth For (gggttagtagttga
tattttttgtttgttttag) and TERC Meth Rev 2 (cctaaaaaaaataataaccattttttatctaaccc) to
amplify a 107 bp region; Kit Meth For (tgggaggaggggttgttgtt) and Kit Meth Rev 2
(taccaccctcccaaacacaaacttc) to amplify a 210 bp region; and SNORD 10 Meth For
(ggtggttatggtattaggagattatatggg) and SNORD 10 Meth Rev (ctcttcccccaaaaaaaaacca
acatcc) to amplify a 219 bp region. All PCRs reactions were performed using a 2-min
hot start at 95uC, followed by 35–40 cycles at 94uC for 20 s, 54uC for 20 s, and 72uC
for 45 s, ending with a 2-min extension at 72uC using GoTaq Green (Promega). PCR
products were gel purified from agarose gels using QiaQuick gel extraction kit
(QIAGEN) and subsequently cloned into the pCR4-TOPO vector (Invitrogen/Life
Technologies). Six independent clones for each target region were sequenced
(Retrogen) using the primers M13 For (220) and M13 Rev. Sequences were then
aligned and analyzed using VectorNTi AlignX (Invitrogen/Life Technologies).
Treatment of melanoma cells with 5-aza-2’-deoxycytidine (5AzadC). Stage III
melanoma cells (WM1552C) were plated into 75-cm2 flasks at a concentration of
5 3 105 cells per flask. Each flask was treated with 10 mg/mL 5AzadC, with a control
flask left untreated. The cells were then washed daily with PBS, given fresh media, and
treated as described above. Treatment was continued for 5 days after which the cells
were washed again with PBS, trypsinized and harvested, and centrifuged at 1200 rpm
for 5 min. Total RNA was extracted from the cell pellets with Trizol reagent
(Invitrogen/Life Technologies), and quantified using the ND-1000
spectrophotometer (NanoDrop). Each assay was performed in triplicate.
High-throughput sequencing. Methylated regions were enriched using LifeTech
MethylMinerTM Methylated DNA Enrichment kit (LifeTech, Foster City, CA). The
SOLiDTM System Fragment Library Preparation protocol was followed per the
manufacturer’s instructions (LifeTech, Foster City, CA, USA). Emulsion PCR (ePCR)
was performed according to standard LifeTech SOLiDTM 3.0 System. Templated
beads were deposited onto two slide quadrants per sample and sequencing was
carried out to 50 bases using SOLiDTM v3.0 chemistry and the manufacturer’s
instructions.
Sequence data processing. The human genome NCBI Build 37/hg19 (downloaded
from UCSC) was used for the mapping and data analysis. The raw data from SOLiDTM
3.0 instrument were pre-processed using SETS software (v3.5, LifeTech, Foster City,
CA) for image analysis, color calling and run quality metrics respectively. Then the
color-space raw reads were mapped to human genome using Bowtie aligner
(v0.12.5)77, allowing a maximum of three mismatches per reads. Only uniquely
mapped reads were retained for further data analysis. For each sample, the aligned
reads from two technical replicates were pooled together to provide greater coverage
for identifying the potential methylation regions in this study.
Identification of methylated regions. Each MBD2-pulldown and its corresponding
input sample DNA was sequenced as above. The uniquely mapped reads were
processed using MACS 1.4 for peak identification78. The enriched methylated regions
were called by comparing the pooled samples with the input control, with a p-value of
less than 1.0E-10 as cutoff using Poisson distribution model in MACS. All
methylation regions were converted into wiggle format for downstream data analysis
and visualization in UCSC genome browser. The Circos software79 was applied to
visualize the genome-wide distribution of the methylation patterns.
RNA-sequencing and data analysis. Total RNA was obtained from melanocyte,
WM1552C and 5AzadC treated WM1552C cell lines using standard RNA isolation
techniques, and fragmented by RNAaseIII digestion. Reverse transcription of these
RNAs will be primed from a ligated primer, and the resulting cRNA will be amplified
and size-selected (150 , 250 bp) for sequencing on a 6% urea gel with the help of
SYBR Gold dye. Sequencing library preparation and emulsion PCR were performed
based on standard LifeTech protocols (LifeTech, Foster City, CA, USA), and short
read sequencing was carried out to 50 bases using SOLiDTM v3.0 chemistry.
The raw RNA-seq data were aligned to hg19 reference genome using Bowtie aligner
(v0.12.5)77, and TopHat80. The mapping results were converted into big wiggle format
and visualized in same UCSC genome browser session as methylation data. RNA-seq
quantification and differential expression analysis were performed used RNA-seq
workflow in the Partek Genomics SuiteTM (version 6.5, Partek Inc, St. Louis, MO).
Briefly, the Partek workflow summarized the transcript abundance based on RefSeq
transcripts using Expectation-Maximization (EM) approach. The reads per kilobase
of transcript per million mapped sequence reads (RPKM) were computed, and
ANOVA was applied for transcript-level differential expression detection.
Transcripts with RPKM less than 1 in all the study samples were filtered out from
further analysis.
Estimating size distribution of the methylated CpG islands. The CpG islands were
downloaded both from UCSC Genome Browser (version hg19, 28,691 islands), and
the newly defined CpG islands based on a Hidden Markov Model81 (http://
rafalab.jhsph.edu/CGI/, 65,699 islands). The final CpG islands (72,145 islands) were
generated from a union of the two annotations. To determine the size distributions,
we accepted the methylated regions identified by MACS as potential methylated CpG
islands, and the frequency for each length class was computed by normalizing the
number of methylated CpG islands exhibiting this length by the total number of
methylated CpG islands identified.
Association of CpG islands with extraneous features. To assess the potential
functions of methylated CpG islands, we extended each island boundary by 200 bp in
both upstream and downstream directions and looked for overlaps with other
features such as lncRNA, promoter, gene structure, etc. Genomic regions were
defined based on NCBI Build 37/hg19 coordinates downloaded from the UCSC web
site. Long noncoding RNA annotations were identified from a pool of the human
GenCode v1282 and the UCSC Human ‘‘All mRNA’’ transcripts83 by a process of
exclusion (i.e. those transcripts that cannot be defined as protein-coding are
considered to be noncoding). Protein-coding transcripts were classified if they met
any of the following criteria: (1) any exon overlapped by 1 bp or more with the exon
(CDS or UTR) of a GenCode protein-coding gene; (2) were defined as protein-coding
using Coding Potential Calculator84; or (3) contained an open reading frame greater
than 120 codons that comprised more than one third of the transcript length. All
remaining transcripts were classified as noncoding. In addition the protein-coding
classification was overridden if the transcript was annotated in lncRNAdb85.
Hierarchical clustering of methylminer data. For this analysis the regulatory region
was defined as a 2000 bp window centered around each TSS (http://dbtss.hgc.jp/).
We chose only the cancer related genes extracted from the CancerGene66 database.
Genes whose regulatory regions showed no methylation in all five cell lines were
excluded; 3,688 genes remained after this filtering. We estimated the methylation
level of each gene’s regulatory region in a specific cell line using the number of reads
that have been mapped within that region. The number of reads was normalized into
effective reads by equating the total number of reads per cell line to the total number
of reads in the input control. The fold change for each gene’s regulatory region in each
cell line was computed as the ratio of the effective read at this region of the sample to
that of the input/control. The fold change for each gene across different cell lines was
further normalized such that the fold change had a mean of 0 and standard deviation
of 6 1.0. Dendrograms were created using hierarchical clustering implemented in
MATLAB using Pearson’s correlation coefficient method.
Other computational and statistical methods. GO functional enrichment analysis
of the CpG-associated genes was conducted by the Ingenuity Pathway Analysis
software suite (IPA Ingenuity Systems, www.ingenuity.com). Fisher’s Exact Test P-
values were adjusted for false discovery rate by the Benjamini-Hochberg correction
with P cut-off at 0.05 (or –log P . 1.3). Gene co-expression network was constructed
by querying the integrated gene interaction database GeneMANIA86; GO enrichment
of the connected network component was measured using GOStat87 (http://
gostat.wehi.edu.au/); protein-protein interaction networks were constructed by
querying GeneMANIA and all network data were analyzed using Cytoscape88.
Student’s t-test and Fisher’s Exact test were also performed to compute the significant
level of differential distribution of methylated using MATLAB.
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